OCULAR THERAPEUTIX INC
(NASDAQ: OCUL)

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company�s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. The Company�s hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company�s product candidates are OTX-DP and OTX-TP. OTX-DP is in Phase III clinical development for post-surgical ocular inflammation and pain. OTX-TP is in Phase II clinical development for glaucoma and ocular hypertension. These product candidates combine its hydrogel technology with the United States Food and Drug Administration (FDA), approved therapeutic agents with the goal of providing sustained delivery of drug to the eye.

9.080

-0.230 (-2.47%)
Range 9.060 - 9.495   (4.80%)
Open -
Previous Close 9.310
Bid Price 6.660
Bid Volume 9
Ask Price 6.670
Ask Volume 8
Volume 2,199,080
Value -
Remark
Delayed prices. Updated at 29 Mar 2024 03:59.
Data powered by
View All Events

About OCULAR THERAPEUTIX INC

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company�s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. The Company�s hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company�s product candidates are OTX-DP and OTX-TP. OTX-DP is in Phase III clinical development for post-surgical ocular inflammation and pain. OTX-TP is in Phase II clinical development for glaucoma and ocular hypertension. These product candidates combine its hydrogel technology with the United States Food and Drug Administration (FDA), approved therapeutic agents with the goal of providing sustained delivery of drug to the eye.

Loading Chart...

Please login to view stock data and analysis